The cluster is small and stale; the revenue decline and lack of insider buying limit conviction. Watch for Q4 2026 results and Phase 2 MOMENTUM trial enrollment completion in Q1 2027 as potential catalysts.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $3.10entry
- T+1 · 8d ago +1.61%α −0.75% · $3.15
- T+5 · 4d ago −10.97%α −13.56% · $2.76
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
How similar events traded
Executive Summary
Five institutional investors added to C4 Therapeutics positions in Q3 2026, with Candriam S.c.a. and Barclays making the largest percentage increases, while Citigroup trimmed. The cluster shows net buying of $497K against $187K in selling, but the moves are small relative to the company's $384M market cap and the 13F data is stale (quarter-end). The cluster follows a Q3 earnings report showing a 24.6% YoY revenue decline, though the company's cash runway to end-2028 provides a buffer.
Key Financial Metrics
Institutional Positions
Net institutional flow: $497.0K
▲ Buyers (5)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Candriam S.c.a. | ADD | +53.6% | $9.2M | $842.0K |
| Barclays | ADD | +98.3% | $492.0K | $144.0K |
| Congress Asset Management | ADD | +25.2% | $4.2M | -$501.0K |
▼ Sellers (1)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Citigroup | TRIM | -73.3% | $231.0K | -$187.0K |
Key Facts
- 5 institutional buyers added positions totaling $497K net; 1 seller trimmed $187K
- Candriam S.c.a. added 963.4K shares (+53.6%), the largest dollar increase at $842K
- Barclays added 73.3K shares (+98.3%), the largest percentage increase
- Citigroup trimmed 36.2K shares (-73.3%), the only seller
- Q3 2026 revenue was $8.5M, down 24.6% YoY; net loss improved to $21.8M from $32.2M
- Cash position $274.7M expected to fund operations to end of 2028
- No open-market insider buying in the window; institutions-only signal
Financial Impact
5 institutions accumulated $14.5M in current holdings (net change +$497K) while 1 institution reduced holdings by $187K
Risk Factors
- 13F data is 45+ days stale; positions may have been unwound
- Revenue declined 24.6% YoY due to conclusion of Merck collaborations
- No insider buying to corroborate institutional conviction
- Cluster is small relative to market cap; signal is weak
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-CCCC-2026-Q3 |
Track record
19 reports on CCCC
5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +46.29% at T+60 after the Apr 9, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.71 settles Nov 23
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $2.76 settles Nov 20
- Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Viewing Entry $3.10 to $2.76 ▼ −10.97% −13.56% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $2.95 to $2.77 ▼ −6.10% −9.39% vs SPY
- Sep 25, 20267w ago 8-K Neutral 4/10 Entry $2.98 to $2.95 ▼ −1.01% −0.79% vs SPY
- Sep 25, 20267w ago Press Release Neutral 4/10 Entry $2.98 to $2.95 ▼ −1.01% −0.79% vs SPY
- Aug 14, 202613w ago 144 Neutral 3/10 Entry $4.27 to $4.10 ▼ −3.87% −2.68% vs SPY
- Aug 14, 202613w ago Institutional Cluster Bullish 6/10 Entry $4.27 to $4.10 ▼ −3.87% −2.68% vs SPY
- Aug 11, 202613w ago 8-K Neutral 5/10 Entry $3.87 to $4.18 ▲ +8.01% +8.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers